Cansortium Closes Non-Brokered Equity Private Placement

Rhea-AI Summary

Cansortium Inc. announced the closing of a non-brokered equity private placement, issuing 3,571,428 common shares at $0.70 per share, raising approximately $2.5 million. The funds will be used for working capital, including potentially exercising an equity cure right under its $71 million Credit Agreement should amendments not be reached with lenders. The securities are not registered under U.S. laws and cannot be offered or sold in the U.S. without proper registration or exemptions.

Positive

• Raised approximately $2.5 million from the equity private placement.
• Funds intended for working capital may strengthen financial stability.

Negative

• Dependence on amending the $71 million Credit Agreement indicates potential financial risk.
• If no amendment is reached, the company may have to rely on equity cure rights, signaling possible liquidity issues.

MIAMI, Dec. 6, 2021 /PRNewswire/ - Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating under the Fluent™ brand, today announced the closing of a non-brokered equity private placement. In total, the Company issued 3,571,428 common shares at a price of $0.70 per share for total proceeds of approximately US$2.5 million.

The Company intends to use net proceeds from the private placement for working capital purposes. The Company is in discussion with its lenders on the $71 Million Credit Agreement to amend such agreement. In the event that no agreement is reached on an amendment, the Company would also designate the proceeds from the private placement to the exercise of its equity cure right under the $71 Million Credit Agreement and the calculation of the consolidated interest coverage ratio thereunder. The Company is entitled to exercise its equity cure right for up to two consecutive quarters.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The securities being offered have not been, nor will they be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws. Accordingly, these securities may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Cansortium in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Cansortium Inc.
Cansortium is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania, Michigan and Texas. The Company operates under the Fluent™ brand and is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Cansortium's unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in Miami, Florida.

Cansortium Inc.'s common shares trade on the CSE under the symbol "TIUM.U" and on the OTCQX Best Market under the symbol "CNTMF". For more information about the Company, please visit www.getfluent.com.

Forward-Looking Information
Certain information in this news release may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates, and projections regarding future events.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Company Contact
Robert Beasley, CEO
(305) 900-6266
www.getfluent.com

Investor Relations Contact
Sean Mansouri, CFA
Elevate IR
(949) 200-4603
investors@cansortium.com

Media Contact
Julie Dietel
Grasslands: A Journalism-Minded Agency
(978) 502-7705
julie@mygrasslands.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cansortium-closes-non-brokered-equity-private-placement-301437660.html

SOURCE Cansortium Inc

FAQ

What is the recent funding raised by Cansortium (CNTMF)?

Cansortium raised approximately $2.5 million through a non-brokered equity private placement.

How many shares did Cansortium issue in their recent private placement?

Cansortium issued 3,571,428 common shares at a price of $0.70 each.

What will Cansortium do with the proceeds from the private placement?

The proceeds will be used for working capital and possibly for exercising equity cure rights under their $71 million Credit Agreement.

Is Cansortium's private placement registered under U.S. law?

No, the securities offered in the private placement are not registered under the U.S. Securities Act and cannot be sold in the U.S. unless registered or exempt.

What financial risks does Cansortium face after their private placement?

Cansortium's reliance on amending their $71 million Credit Agreement suggests potential financial risk, and they may need to utilize equity cure rights if an amendment is not reached.